February 2012 Infectious Disease

Pharmacists can prepare for change by taking careful stock of the services they want to provide now and in the future.

The growth of this field is dependent upon connecting stakeholders in a productive way.

The FDA approved Lazanda (fentanyl) nasal spray for the management of breakthrough pain in opioid-tolerant cancer patients 18 years or older.

Some important safety measures, such as asking open-ended questions, are neither complicated nor costly.

As more patients begin medication regimens that include rivaroxaban, pharmacists should be aware of its known interactions.

When patients ask about this troublesome ophthalmic condition, pharmacists can recommend helpful management techniques.

Elizabeth O'Hara puts patients at ease with her compassionate, and sometimes humorous, approach.

Topical preparations can relieve the symptoms of both allergic and irritant contact dermatitis.

When recommending OTC products for these common ailments, a careful patient assessment is an important first step.

Is a pharmacy liable when an employee releases private health information about a patient?

A new formulation of hydrocodone currently in development has lawmakers and drug abuse prevention professionals concerned.

With an all-oral combination therapy and a hepatitis C vaccine on the horizon, pharmacists and patients will soon have new resources against this prevalent infection.

As blockbuster drugs begin losing patent protection, pharmaceutical companies and pharmacists will address key marketplace changes.

Patients taking antiretroviral therapy can maximize their therapy when pharmacists educate them about their medication regimens.